Differential salutary effects of nonselective and selective COX-2 inhibitors in postoperative ileus in rats

J Surg Res. 2003 Feb;109(2):161-9. doi: 10.1016/s0022-4804(02)00095-1.

Abstract

Background: Postoperative ileus (PI) is a common surgical complication, the treatment of which consists of supportive measures.

Aim: The effects of several cyclooxygenase (COX) inhibitors and their interaction with L-arginine/nitric oxide synthase (NOS) pathway were tested in a rat PI model.

Methods: Intestinal transit was measured as Evans blue migration after skin incision, laparotomy, or laparotomy followed by evisceration and gut handling.

Results: In contrast to a selective inducible NOS (iNOS) blocker, L-N(6)-(1-iminoethyl)lysine hydrochloride (L-NIL), N(omega)-nitro-L-arginine methyl ester (L-NAME) reversed the additional inhibitory effects of gut manipulation after laparotomy on the gastrointestinal transit (GI) in a dose-dependent, L-arginine-sensitive manner. Laparotomy and manipulations of small intestine increased blood plasma nitrites and nitrates level (NOx), an effect preventable by L-NAME. Indomethacin, resveratrol (selective COX-1 blocker), and COX-2 antagonists, nimesulide, NS-398, DuP-697, and L-752860, attenuated the additional inhibitory effects of gut manipulation following laparotomy in a dose-dependent manner. In contrast, only nimesulide, NS-398, DuP-697, and L-752860 partly, but significantly, reversed the effects of laparotomy on the intestinal transit. Administration of L-NAME subsequent to COX inhibitors abolished the salutary effects of the latter, implying that at least the synthesis of either NO or prostanoids must remain unaffected to enable a return of GI transit during the postoperative period.

Conclusion: In addition to NO synthesized by constitutive NOS (cNOS), prostaglandins produced by both COX-1 and COX-2 participate in the pathogenesis of PI, albeit in different pathological mechanisms. Thus laparotomy stimulated COX-2 activity, whereas gut manipulation led to an excessive cNOS activity and prostaglandin synthesis by COX-1.

Publication types

  • Comparative Study
  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arginine / pharmacology
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / pharmacology*
  • Enzyme Inhibitors / pharmacology
  • Gastrointestinal Motility / drug effects*
  • Intestinal Pseudo-Obstruction / drug therapy*
  • Intestines / drug effects*
  • Intestines / surgery*
  • Isoenzymes / antagonists & inhibitors*
  • Laparotomy / adverse effects
  • Lysine / analogs & derivatives*
  • Lysine / pharmacology
  • Male
  • Models, Animal
  • NG-Nitroarginine Methyl Ester / pharmacology
  • Nitric Oxide / blood
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Nitric Oxide Synthase Type II
  • Postoperative Complications*
  • Prostaglandin-Endoperoxide Synthases
  • Prostaglandins / biosynthesis
  • Prostaglandins / physiology
  • Rats
  • Rats, Wistar

Substances

  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Enzyme Inhibitors
  • Isoenzymes
  • N(6)-(1-iminoethyl)lysine
  • Prostaglandins
  • Nitric Oxide
  • Arginine
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type II
  • Nos2 protein, rat
  • Cyclooxygenase 2
  • Prostaglandin-Endoperoxide Synthases
  • Lysine
  • NG-Nitroarginine Methyl Ester